Clinical Trial Update: A Single-Dose Study of Tivozanib in Subjects With Hepatic Impairment and Normal Hepatic Function [Phase 1]

View source ↗

Summary

Phase 1, single-dose pharmacokinetic study evaluating tivozanib in subjects with hepatic impairment compared to those with normal hepatic function.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Liver Disease

Drugs mentioned

• Tivozanib (tivozanib)

Snippet

Sponsor: AVEO Pharmaceuticals, Inc. | Conditions: Hepatic Impairment | Phase 1 | Status: COMPLETED